LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: New tests for null hypothesis of non unity ratio of proportions.

    Koti, Kallappa M

    Journal of biopharmaceutical statistics

    2007  Volume 17, Issue 2, Page(s) 229–245

    Abstract: Testing for noninferiority and equivalence between an experimental therapy and a standard therapy in terms of the ratio of binomial proportions is considered. New tests based on the Fieller-Hinkley distribution of the ratio of random variables are ... ...

    Abstract Testing for noninferiority and equivalence between an experimental therapy and a standard therapy in terms of the ratio of binomial proportions is considered. New tests based on the Fieller-Hinkley distribution of the ratio of random variables are proposed. Restricted maximum likelihood estimates of the null variances are used to derive the tests. Sample size determination is discussed. The proposed test procedure is extended to multiple tables. The tests are applied to numerical examples.
    MeSH term(s) Confidence Intervals ; Controlled Clinical Trials as Topic/methods ; Controlled Clinical Trials as Topic/standards ; Controlled Clinical Trials as Topic/statistics & numerical data ; Data Interpretation, Statistical ; Humans ; Models, Statistical ; Research Design/standards ; Research Design/statistics & numerical data ; Sample Size
    Language English
    Publishing date 2007
    Publishing country England
    Document type Journal Article
    ZDB-ID 1131763-2
    ISSN 1520-5711 ; 1054-3406
    ISSN (online) 1520-5711
    ISSN 1054-3406
    DOI 10.1080/10543400601177426
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3511: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Use of the Fieller-Hinkley distribution of the ratio of random variables in testing for noninferiority.

    Koti, Kallappa M

    Journal of biopharmaceutical statistics

    2007  Volume 17, Issue 2, Page(s) 215–228

    Abstract: We address the noninferiority assessment problem defined in terms of the ratio of population means in a parallel group design analysis of variance setting. The sample ratio as a point estimate of the corresponding population ratio has been considered. It ...

    Abstract We address the noninferiority assessment problem defined in terms of the ratio of population means in a parallel group design analysis of variance setting. The sample ratio as a point estimate of the corresponding population ratio has been considered. It has been shown that the Fieller-Hinkley distribution of the ratio of two correlated normally distributed random variables readily provide a technique for constructing confidence intervals comparable to the bootstrap percentile and Fieller's confidence intervals. A finite parameter space based level alpha test of an inferiority hypothesis formulated in terms of a fixed margin has been derived. We illustrate our approach using the forced vital capacity (FVC) data. We claim that it is easy to construct and straight forward to interpret our bootstrap equivalent confidence intervals that are used to assess noninferiority. We discuss appropriate methods for calculation of sample sizes.
    MeSH term(s) Confidence Intervals ; Controlled Clinical Trials as Topic/methods ; Controlled Clinical Trials as Topic/standards ; Controlled Clinical Trials as Topic/statistics & numerical data ; Data Interpretation, Statistical ; Humans ; Models, Statistical ; Research Design/standards ; Research Design/statistics & numerical data ; Sample Size
    Language English
    Publishing date 2007
    Publishing country England
    Document type Journal Article
    ZDB-ID 1131763-2
    ISSN 1520-5711 ; 1054-3406
    ISSN (online) 1520-5711
    ISSN 1054-3406
    DOI 10.1080/10543400601177335
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3511: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

    Herndon, Thomas M / Deisseroth, Albert / Kaminskas, Edvardas / Kane, Robert C / Koti, Kallappa M / Rothmann, Mark D / Habtemariam, Bahru / Bullock, Julie / Bray, Jeffrey D / Hawes, Jessica / Palmby, Todd R / Jee, Josephine / Adams, William / Mahayni, Houda / Brown, Janice / Dorantes, Angelica / Sridhara, Rajeshwari / Farrell, Ann T / Pazdur, Richard

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2013  Volume 19, Issue 17, Page(s) 4559–4563

    Abstract: The U.S. Food and Drug Administration (FDA) review leading to accelerated approval of carfilzomib is described. A single-arm trial enrolled 266 patients with multiple myeloma refractory to the most recent therapy who had received prior treatment with ... ...

    Abstract The U.S. Food and Drug Administration (FDA) review leading to accelerated approval of carfilzomib is described. A single-arm trial enrolled 266 patients with multiple myeloma refractory to the most recent therapy who had received prior treatment with bortezomib and an immunomodulatory agent (IMID). Patients received carfilzomib by intravenous infusion over 2 to 10 minutes at a dose of 20 mg/m2 on days 1, 2, 8, 9, 15, and 16 of the 28 days of cycle 1, and at a dose of 27 mg/m2 on the same schedule in cycle 2 and subsequent cycles. The primary efficacy endpoint was overall response rate (ORR) as determined by an independent review committee using International Myeloma Working Group Uniform Response Criteria. The safety of carfilzomib was evaluated in 526 patients with multiple myeloma treated with various dosing regimens. The ORR was 23%. The median duration of response was 7.8 months. The most common adverse reactions associated with carfilzomib infusion were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and fever. The most common serious adverse events were pneumonia, acute renal failure, fever, and congestive heart failure. Infusion reactions to carfilzomib could be reduced by pretreatment with dexamethasone and intravenous fluids. On July 20, 2012, the FDA granted accelerated approval of carfilzomib for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an IMID and who have shown disease progression while on therapy or within 60 days of completion of the last therapy.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Clinical Trials as Topic ; Drug Approval ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Oligopeptides/adverse effects ; Oligopeptides/therapeutic use ; Proteasome Inhibitors/adverse effects ; Proteasome Inhibitors/therapeutic use ; United States ; United States Food and Drug Administration
    Chemical Substances Oligopeptides ; Proteasome Inhibitors ; carfilzomib (72X6E3J5AR)
    Language English
    Publishing date 2013-09-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-13-0755
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top